Description
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Location: SIMR (Sacramento/Roseville/Auburn)
Please contact: SIMR@sutterhealth.org about study Guardant Health 02-MX-003 ORACLE
Principal Investigator
Co-Investigator(s)
Jaspreet K Dhillon, Medical Oncologist, Sivakumar Reddy, M.D., Vijay Suhag, M.D., Rajeswari Chellappah, M.D., Kristie A. Bobolis, M.D., Kristin N. Arreola, M.D., Brian K. Kim, M.D